Bio Blast Pharma Company Profile (NASDAQ:ORPN)

About Bio Blast Pharma (NASDAQ:ORPN)

Bio Blast Pharma logoBioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich's ataxia) and BBrm-02. The Company's product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ORPN
  • CUSIP: N/A
  • Web: bioblastpharma.com
Capitalization:
  • Market Cap: $7.25 million
  • Outstanding Shares: 3,342,000
Average Prices:
  • 50 Day Moving Avg: $2.55
  • 200 Day Moving Avg: $2.71
  • 52 Week Range: $1.49 - $8.55
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.97
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.41 per share
  • Price / Book: 1.54
Profitability:
  • EBITDA: ($9,960,000.00)
  • Return on Equity: -155.26%
  • Return on Assets: -128.89%
Debt:
  • Current Ratio: 6.97%
  • Quick Ratio: 6.97%
Misc:
  • Average Volume: 79,352 shs.
  • Beta: -0.11
  • Short Ratio: 0.94
 

Frequently Asked Questions for Bio Blast Pharma (NASDAQ:ORPN)

What is Bio Blast Pharma's stock symbol?

Bio Blast Pharma trades on the NASDAQ under the ticker symbol "ORPN."

When did Bio Blast Pharma's stock split? How did Bio Blast Pharma's stock split work?

Shares of Bio Blast Pharma reverse split on Monday, September 25th 2017. The 1-5 reverse split was announced on Monday, September 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 22nd 2017. An investor that had 100 shares of Bio Blast Pharma stock prior to the reverse split would have 20 shares after the split.

How were Bio Blast Pharma's earnings last quarter?

Bio Blast Pharma Ltd. (NASDAQ:ORPN) posted its quarterly earnings results on Thursday, August, 25th. The company reported ($1.10) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.35) by $0.25. During the same period in the prior year, the company earned ($1.30) EPS. View Bio Blast Pharma's Earnings History.

When will Bio Blast Pharma make its next earnings announcement?

Bio Blast Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, December, 5th 2017. View Earnings Estimates for Bio Blast Pharma.

Where is Bio Blast Pharma's stock going? Where will Bio Blast Pharma's stock price be in 2017?

1 brokerages have issued twelve-month price targets for Bio Blast Pharma's shares. Their predictions range from $3.15 to $75.00. On average, they anticipate Bio Blast Pharma's share price to reach $39.08 in the next year. View Analyst Ratings for Bio Blast Pharma.

Who are some of Bio Blast Pharma's key competitors?

How do I buy Bio Blast Pharma stock?

Shares of Bio Blast Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio Blast Pharma's stock price today?

One share of Bio Blast Pharma stock can currently be purchased for approximately $2.17.


MarketBeat Community Rating for Bio Blast Pharma (NASDAQ ORPN)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about Bio Blast Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Bio Blast Pharma (NASDAQ:ORPN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $39.08 (1,700.69% upside)
Consensus Price Target History for Bio Blast Pharma (NASDAQ:ORPN)
Price Target History for Bio Blast Pharma (NASDAQ:ORPN)
Analysts' Ratings History for Bio Blast Pharma (NASDAQ:ORPN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/28/2017S&P Equity ResearchBoost Price Target$2.80 -> $3.15LowView Rating Details
10/24/2016Roth CapitalSet Price TargetBuy$75.00N/AView Rating Details
7/11/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
1/28/2016HC WainwrightInitiated CoverageBuy$125.00N/AView Rating Details
11/27/2015Oppenheimer Holdings, Inc.Reiterated RatingOutperform$160.00N/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Bio Blast Pharma (NASDAQ:ORPN)
Earnings by Quarter for Bio Blast Pharma (NASDAQ:ORPN)
Earnings History by Quarter for Bio Blast Pharma (NASDAQ ORPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/27/2017N/AView Earnings Details
8/25/2016Q2($1.35)($1.10)ViewN/AView Earnings Details
5/25/2016Q1($1.45)($1.60)ViewN/AView Earnings Details
2/23/2016Q4($1.25)($1.70)ViewN/AView Earnings Details
11/17/2015Q3($1.45)($1.25)ViewN/AView Earnings Details
8/21/2015Q2($1.40)($1.30)ViewN/AView Earnings Details
5/19/2015Q115($1.25)($1.15)ViewN/AView Earnings Details
2/17/2015Q414($0.80)($1.10)ViewN/AView Earnings Details
11/21/2014($0.45)($0.80)ViewN/AView Earnings Details
8/29/2014Q214($0.45)($0.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio Blast Pharma (NASDAQ:ORPN)
Current Year EPS Consensus Estimate: $-0.82 EPS
Next Year EPS Consensus Estimate: $-0.73 EPS

Dividends

Dividend History for Bio Blast Pharma (NASDAQ:ORPN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bio Blast Pharma (NASDAQ:ORPN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Bio Blast Pharma (NASDAQ:ORPN)
Latest Headlines for Bio Blast Pharma (NASDAQ:ORPN)
Source:
DateHeadline
finance.yahoo.com logoBioblast Announces Effectiveness of Five to One Reverse Split
finance.yahoo.com - October 2 at 9:20 PM
americanbankingnews.com logoHead to Head Review: Bio Blast Pharma (ORPN) versus Its Peers
www.americanbankingnews.com - September 30 at 6:26 AM
finance.yahoo.com logoBioblast Pharma Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 5 at 5:38 AM
finance.yahoo.com logoBio Blast reports 2Q loss
finance.yahoo.com - August 5 at 5:38 AM
streetinsider.com logoBioBlast Pharma (ORPN) to Seek Strategic Alternatives Including Partnership or Merger - StreetInsider.com
www.streetinsider.com - June 6 at 8:24 AM
globenewswire.com logoBioblast Pharma Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
www.globenewswire.com - May 28 at 5:26 AM
nasdaq.com logoBioblast Pharma Reports First Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - May 26 at 8:14 PM
nasdaq.com logoBioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders' Equity and Minimum ... - Nasdaq
www.nasdaq.com - April 20 at 12:08 AM
us.rd.yahoo.com logoBioblast Pharma Announces Receipt of Nasdaq Notification Regarding Stockholders’ Equity
us.rd.yahoo.com - March 10 at 8:52 PM
us.rd.yahoo.com logoBioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results
us.rd.yahoo.com - February 24 at 8:45 AM
us.rd.yahoo.com logoBioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and Other Neurodegenerative Diseases
us.rd.yahoo.com - February 2 at 7:59 PM
us.rd.yahoo.com logo4:02 pm Bio Blast Pharma announces clinical update related to its proprietary intravenous (:IV) form of trehalose 90 mg/mL solution, which is being evaluated as a potential therapeutic, initially for oculopharyngeal muscular dystrophy
us.rd.yahoo.com - February 2 at 7:59 PM

Social

Chart

Bio Blast Pharma (ORPN) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.